BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8714272)

  • 1. Donor leukocyte infusions in the treatment of chronic myeloid leukemia in relapse post bone marrow transplantation.
    Hill GR; Hart DN; Moore AF; Morris CM
    Pathology; 1996 Jan; 28(1):51-3. PubMed ID: 8714272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
    Bär BM; Schattenberg A; Mensink EJ; Geurts Van Kessel A; Smetsers TF; Knops GH; Linders EH; De Witte T
    J Clin Oncol; 1993 Mar; 11(3):513-9. PubMed ID: 8445426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
    Baurmann H; Nagel S; Binder T; Neubauer A; Siegert W; Huhn D
    Blood; 1998 Nov; 92(10):3582-90. PubMed ID: 9808551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Drobyski WR; Roth MS; Thibodeau SN; Gottschall JL
    Bone Marrow Transplant; 1992 Sep; 10(3):301-4. PubMed ID: 1422483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular remission induced by fractionated dose-escalating donor leukocyte infusion without graft-versus-host disease in a patient with chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation.
    Inai K; Wano Y; Yamamoto S; Ikebata Y; Iwasaki H; Tsutani H; Naiki H; Ueda T
    Anticancer Res; 1999; 19(6C):5631-4. PubMed ID: 10697631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemia: management of relapse after allogeneic bone marrow transplantation.
    Kumar L
    J Clin Oncol; 1994 Aug; 12(8):1710-7. PubMed ID: 8040682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia.
    Keil F; Haas OA; Fritsch G; Kalhs P; Lechner K; Mannhalter C; Reiter E; Niederwieser D; Hoecker P; Greinix HT
    Blood; 1997 May; 89(9):3113-7. PubMed ID: 9129013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J; Alvarez MA; Torres A
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of molecular remission by donor peripheral blood leukocyte therapy in patients relapsing with extramedullary blastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation.
    Bashey A; Shepherd S; Frankel W; Wang-Rodriguez J; Cahill T; Chamberlain M; Mason JR; Ho AD; Corringham RE
    Oncol Rep; 1998; 5(1):281-5. PubMed ID: 9458334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achievement of complete cytogenetic remission after two very low-dose donor leucocyte infusions in a patient with extensive cGVHD relapsing in accelerated phase post allogeneic BMT for CML.
    Rahman SL; Mahendra P; Nacheva E; Sinclair P; Arno J; Marcus RE
    Bone Marrow Transplant; 1998 May; 21(9):955-6. PubMed ID: 9613792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Red blood cell phenotyping is a sensitive technique for monitoring chronic myeloid leukaemia patients after T-cell-depleted bone marrow transplantation and after donor leucocyte infusion.
    Schaap N; Schattenberg A; Bär B; Mensink E; de Man A; Geurts van Kessel A; de Witte T
    Br J Haematol; 2000 Jan; 108(1):116-25. PubMed ID: 10651734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
    Porter DL; Roth MS; McGarigle C; Ferrara JL; Antin JH
    N Engl J Med; 1994 Jan; 330(2):100-6. PubMed ID: 8259165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Matsue K; Tabayashi T; Yamada K; Takeuchi M
    Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse.
    van Rhee F; Lin F; Cullis JO; Spencer A; Cross NC; Chase A; Garicochea B; Bungey J; Barrett J; Goldman JM
    Blood; 1994 Jun; 83(11):3377-83. PubMed ID: 8193375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
    Hertenstein B; Wiesneth M; Novotny J; Bunjes D; Stefanic M; Heinze B; Hübner G; Heimpel H; Arnold R
    Transplantation; 1993 Nov; 56(5):1114-8. PubMed ID: 8249110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor lymphocyte infusion followed by interferon-alpha plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Leda M; Ladon D; Pieczonka A; Boruczkowski D; Jólkowska J; Witt M; Wachowiak J
    Leuk Res; 2001 Apr; 25(4):353-7. PubMed ID: 11248334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Leukocyte transfusion as therapy of recurrent CML after allogenic bone marrow transplantation].
    Wiesneth M; Hertenstein B; Bunjes D; Novotny J; Stefanic M; Heinze B; Schreiner T; Kubanek B; Heimpel H; Arnold R
    Beitr Infusionsther Transfusionsmed; 1994; 32():276-80. PubMed ID: 9480108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.
    Mackinnon S; Papadopoulos EB; Carabasi MH; Reich L; Collins NH; Boulad F; Castro-Malaspina H; Childs BH; Gillio AP; Kernan NA
    Blood; 1995 Aug; 86(4):1261-8. PubMed ID: 7632930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.